Sub-millimetric, patient-specific brain targeting for functional neurosurgery and real-world outcomes in Parkinson’s Disease and Essential Tremor.

Rebrain unveils its identity: a strong vision for the future of assisted neurosurgery

At the beginning of this year, the entire Rebrain team extends its best wishes to all our partners and investors and would like to share a retrospective of the key milestones and significant achievements that marked 2025.

At Rebrain, innovation has never been an end in itself. It has always been a means to improve the precision of neurosurgical procedures and to have a concrete impact on patients’ lives. Today, we are reaching a new stage of our development with the official launch of our new visual identity.

Over the past years, our company has undergone a profound transformation.
Our technology has matured.
Our scientific collaborations have strengthened.
Our vision has become more international.

This new brand territory reflects this evolution: more modern, more structured, more ambitious, and above all more aligned with the mission we are pursuing contributing to defining the future of augmented neurosurgery by standardizing targeting.

This new identity embodies this ambition around three fundamental pillars:

  • Precision: Because increased precision helps enhance procedural safety and reduce side effects.
  • Impacting: Because the value of innovation is measured by its real impact on clinical outcomes and patients’ quality of life.
  • Futures: Because tomorrow’s medicine must be part of a sustainable vision, capable of creating long-term value for patients, clinicians, and healthcare systems.

“This new identity reflects the company Rebrain has become today: a company driven by international ambition, strong scientific rigor, and a deep conviction that innovation can sustainably transform patients’ care pathways. This rebranding marks a new stage in our history. It symbolizes our determination to go further, to accelerate our clinical impact, and to continue building the tools that will help define the neurosurgery of tomorrow. We are proud of the journey accomplished and even more excited about the future ahead of us.” – Emmanuel Cuny, CMO and co-founder; Nejib Zemzemi, CSTO and co-founder

Through this transformation, Rebrain reaffirms its commitment to continue building medical technologies with strong scientific, clinical, and human value.

This new identity does not represent an arrival. It marks the beginning of a new phase of growth, innovation, and international ambition.

The future of neurosurgery is being built today.
And Rebrain intends to play a major role in it.

Our latest public updates

RebrAin 2025/2026: Expanding Reach, Driving Innovation

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...

Rebrain publishes OPTIVIM trial results in Neurosurgery

Rebrain publishes OPTIVIM trial results in Neurosurgery

An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...